Reduce the Risk of Recurrence in Early Stage HER2+ Breast Cancer
October 11, 2021
Importance of education in making your own care decisions
Approximately 1 in 8 women, in the United States, will develop invasive breast cancer in their lifetime, and approximately 20% of these women will have HER2-positive breast cancer, a more aggressive form of the disease known for putting its patients at a higher risk of recurrence. Today…an open dialogue about the emotions that can come with a HER2 positive breast cancer diagnosis and ways to be informed and proactive in your treatment decisions.
Walkasins® is a newly available external lower limb sensory prosthesis designed to replace lost nerve function in patients with peripheral neuropathy.
The EB Research Partnership is the largest global organization dedicated to funding research to treat and cure Epidermolysis Bullosa or EB.
Laithwaites is a wine subscription that exclusively selects a range of small-batch, handcrafted wines from top-quality family estates and passionate winemakers from every corner of the world.